ArticleFrontiers in pharmacology2025
Polydatin attenuates Alzheimer's disease induced by aluminum chloride in rats: evidence for its antioxidant and anti-inflammatory effects.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Phytomedicines modulate pyroptosis in cardiovascular diseases: pre-clinical evidence, limitations and translational perspectives.Frontiers in pharmacology · 2026Review
- Polydatin Attenuates Cognitive Deficits and Neuroinflammation by Inhibiting the P2X7/NLRP1 Inflammasome Pathway in APP/PS1 Mice and Aβ-Treated HT22 Cells.Molecular neurobiology · 2025Article
- Role of the NLRP3 inflammasome in diabetes and its complications (Review).Molecular medicine reports · 2025Review
- Plants, Pills, and the Brain: Exploring Phytochemicals and Neurological Medicines.International journal of plant, animal and environmental sciences · 2025Article
- Editorial: Traditional, complementary and integrative medicine - opportunities for managing and treating neurodegenerative diseases and ischaemic stroke.Frontiers in pharmacology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Considering the complex pathophysiological mechanisms behind Alzheimer's disease (AD), a few drugs for managing related cognitive symptoms have been approved. The phytochemical resveratrol has shown promising anti-inflammatory and antioxidant effects in AD, but it has low bioavailability. Chemical modification of resveratrol to its glycosylated form, polydatin (PD), significantly increases its bioavailability and bioactivity. Purpose: The study aimed to investigate the therapeutic potential and mechanisms of action of PD against AD in rats. Material and method: AD was caused by an intraperitoneal (i.p.) administration of aluminum chloride (AlCl Results and discussion: The findings revealed that PD injections at three different doses (5, 10, and 20 mg/kg) improved cognitive and other behavioral impairments. Furthermore, PD improved the antioxidant capacity by increasing GSH and CAT while decreasing serum nitrite levels. PD showed anti-inflammatory effects by reducing the activity of inflammatory MMP-9, while elevating the activity of anti-inflammatory MMP-2. PD also modulated pathogenic changes in the hippocampal brain tissue. Conclusion: PD alleviated cognitive and other behavioral impairments in AD rats by enhancing antioxidant defenses and reducing neuroinflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.